WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v9, COVARIATES include Serum testosterone level, Anatomical region instantiated by -Lung -CNS -Liver -Adrenal (L, R) -Lymph nodes -Other, - CR - PR differentiated into Confirmation Date, COVARIATES include Type of Progression, Bone Scintigraphy provides Image readability, Non-opiate Administration measured at Start Date, Hormonal intervention has attributes Duration of administration, Target lesion evaluated by Quantitative assessment, Type instantiated by - androgen receptor antagonist - androgen synthesis inhibitor - other, Time-To-Event efficacy endpoints include Time to Initiation of Chemotherapy, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Functional Status Impairment measured with Functional Status Assessment Tool, OVERALL RESPONSE derived from Sponsor specified Response Criteria (e.g. RECIST), T U M O R R E S P O N S E is assessed with -MRI -CT, -Complete Response (CR) -Non-CR/non-PD -Not all evaluated -Non-PD -PD summarized into OVERALL RESPONSE, Baseline lesion(s) identified by Baseline lesion ID, Progression Free Survival (PFS) includes Radiographic Progression Free Survival (rPFS), OVERALL RESPONSE have response options -SD -PD -NE (inevaluable), New lesion identified by Organ specific lesion ID, Non-target lesion evaluated by Qualitative Assessment